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Abstract
We report a DNA shuffling–based approach for developing cell type–specific vectors through
directed evolution. Capsid genomes of adeno-associated virus (AAV) serotypes 1–9 were randomly
fragmented and reassembled using PCR to generate a chimeric capsid library. A single infectious
clone (chimeric-1829) containing genome fragments from AAV1, 2, 8, and 9 was isolated from an
integrin minus hamster melanoma cell line previously shown to have low permissiveness to AAV.
Molecular modeling studies suggest that AAV2 contributes to surface loops at the icosahedral
threefold axis of symmetry, while AAV1 and 9 contribute to two- and fivefold symmetry interactions,
respectively. The C-terminal domain (AAV9) was identified as a critical structural determinant of
melanoma tropism through rational mutagenesis. Chimeric-1829 utilizes heparan sulfate as a primary
receptor and transduces melanoma cells more efficiently than all serotypes. Further, chimeric-1829
demonstrates altered tropism in rodent skeletal muscle, liver, and brain including nonhuman primates.
We determined a unique immunological profile based on neutralizing antibody (NAb) titer and
crossreactivity studies strongly supporting isolation of a synthetic laboratory-derived capsid variant.
Application of this technology to alternative cell/tissue types using AAV or other viral capsid
sequences is likely to yield a new class of biological nanoparticles as vectors for human gene transfer.
INTRODUCTION
Adeno-associated virus (AAV) is a 20–25-nm nonpathogenic human parvovirus that has gained
popularity as a vector for gene therapy applications.1-3 Among the 12 identified serotypes,
AAV 1–9 are being developed as gene therapy vectors because of their capsid-associated tissue
tropism for specific tissues.4-7 These naturally occurring AAV serotypes constitute a family
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of capsid backbones that can be exploited for generation of chimeric vectors to enable the
transduction of tissues refractory to AAV infection or limited tropism to specific tissues.
Strategies for retargeting AAV capsids include insertion of peptide ligands, conjugate-based
targeting, and presentation of large protein ligands on the AAV capsid.8-11 The generation of
mosaic vectors through the transcapsidation or marker rescue approach, respectively, is a
notable strategy to expand the tropism of AAV serotypes.12-15 More recently, combinatorial
strategies for engineering AAV vectors using error-prone PCR, DNA shuffling, and other
molecular cloning techniques have been explored.16,17
DNA shuffling is a powerful process for directed evolution, which generates diversity by
recombination, combining useful mutations from individual genes. Single and multigene traits
that require many mutations for improved phenotypes can be evolved rapidly.18-21 Recently,
Schaffer and colleagues have applied a staggered extension process (analogous to single-gene
shuffling) combined with error-prone PCR to the AAV2 capsid gene and selected for variants
that can escape neutralizing antibodies.16 In this study, we have extended the technique by
using a family of multiple AAV genes with different serotype capsid sequences serving as
templates. The combinatorial AAV capsid library generated thus was combined with directed
evolution to select CS1 (hamster melanoma cell) cell line for novel cell type–specific AAV
variants. The CS1 cell line, derived from chinese hamster melanoma is a well-characterized
system for study of integrin–matrix interactions.22 Our lab has successfully used this cell line
to demonstrate that αvβ5 is a coreceptor for AAV2 infection with low permissiveness.23 In
addition, the number of deaths from melanoma worldwide is >50,000/y, of which as high as
54% are directly related to metastases to brain.24 Generating a chimeric vector with propensity
for melanoma cells would provide a significant advancement to the field of cancer gene
delivery. For these reasons, we used this cell line to generate a cell type–specific chimeric
capsid variant that would transduce CS1 melanoma cells. The results described herein illustrate
the tremendous potential of directed evolution in generating novel cell type–specific chimeric
vectors and identifying the molecular determinants of tissue tropisms exhibited by different
capsid motifs. When combined with rational site-directed mutagenesis and molecular modeling
tools, the aforementioned combinatorial approach is expected to unravel structure–function
correlates of the variant capsid down to the amino acid level and through rational design lead
to controlled tropism by simply altering critical amino acids on a parental AAV serotype capsid.
More important, the shuffling of AAV capsid information exchange between various
parvovirus and nonparvovirus capsid sequences should lead to a new generation of novel
biological nanoparticles with distinct immune profile as well as cell- and tissue-specific
tropism.
RESULTS
Generation and characterization of the chimeric AAV library
The chimeric AAV capsid library was generated by DNA shuffling of genes encoding capsid
sequences of AAV serotypes 1–9 (except AAV7) (Figure 1a). The diversity of the library was
determined to be 2 × 106 clones and DNA sequencing of 20 randomly selected clones verified
that the chimeric Cap genes were indeed recombinants from the Cap genes of different parental
AAV serotypes. After establishing the plasmid library, the AAV capsid library was generated
in two additional steps.8 We first partially packaged the library containing recombinant Cap
genes into AAV2 capsids by cotransfection of pXR2 along with the AAV plasmid library. The
resulting AAV library was then used to infect HEK293 cells [multiplicity of infection (MOI)
= 1] and the cells superinfected with adenovirus (Ad) dl309, thus ensuring production of
chimeric AAV capsids packaging the corresponding chimeric AAV genome.
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Directed evolution of a melanoma-specific AAV vector
Directed evolution of a CS1-specific AAV variant was achieved by infecting CS1 cells at an
MOI of 1,000 in the presence of Ad dl309 (MOI = 20). As shown in Figure 1b, repeated cycling
(every 48 h, n = 5) of the AAV library in CS1 cells resulted in an initial decrease in the recovery
of replication-competent AAV as determined by dot blot, followed by evolution of a novel
capsid variant (chimeric-1829). DNA extracted from cell lysate obtained from the fifth cycle
served as a template for PCR using primers P3 and P4. Sequence analysis helped identify the
isolate as a chimera derived from fragments of AAV1, AAV2, AAV8, and AAV9 genomes,
referred to as chimeric-1829 (Figure 2a). Such recombination likely resulted from crossover
at different 5′ and 3′ locations along the capsid-coding region. The first 1,200 base pairs of the
chimeric-1829 Cap gene is derived from the 5′ region of AAV1 Cap, followed by a crossover
including 90 base pairs from AAV8 Cap, a fragment from AAV2 up to nucleotide (nt) 2045,
and the remaining portion derived from the corresponding region in AAV9 Cap. In addition,
three silent mutations at nt 763, 1285, and 2099 were observed.
Structural analysis of chimeric-1829
As shown in Figure 2b, most surface-exposed variable loops in the threefold region of
chimeric-1829 are derived from AAV2, including previously identified heparin-binding
residues.25-27 The heparin-binding assay verified that chimeric-1829 and AAV2 share the
same heparin-binding and elution profiles (Figure 2c). On the contrary, VP3 pentamer
interactions at the fivefold axis of symmetry appear to be mainly derived from AAV1, although
AAV2 contributes to the HI loop (located between βH and βI) that extends to overlap
neighboring VP3 subunits. In addition, residues from AAV1 form part of the raised capsid
surface region between the depressions at the two- and fivefold axes (Figure 2b). The residue
stretch from 264 to 272 derived from AAV1 has been shown to be structurally variable between
the AAV capsids,28,29 and modeling also predicted this variability for chimeric-1829. In
addition, these residues have been shown to affect AAV2 cellular transduction dramatically
and they form a minor part of the A20 epitope.30,31
Regions derived from AAV8 (residues 410–450) are located on the finger-like projection that
forms the protrusions that surround the threefold axis and are mostly buried in the assembled
capsid, with surface-exposed regions adjacent to the regions contributed by AAV1 (Figure 2b).
The AAV9 residues (705–736) are located on the wall of the twofold dimple region and make
contact with AAV1 residues that form the raised capsid region between the icosahedral two-
and fivefold axes (Figure 2b). The AAV1 region between the two- and fivefold axes and the
AAV8 and AAV9 regions, which differ from AAV1/AAV2 capsid sequences by <10 amino
acids, might contribute to the melanoma-tropic trait seen in chimeric-1829 vectors. More
important, the identification of such clusters of residues enables mapping specific regions on
the AAV capsid that can be targeted for rational manipulation.
Biological characterization of chimeric-1829 vectors in vitro
As shown in Figure 3a, chimeric-1829 vectors packaging the green fluorescent protein (GFP)
transgene transduce CS1 cells with a higher efficiency than other AAV serotypes. In addition
to the higher number of transduced cells, the intensity of GFP was also significantly higher for
chimeric-1829. When tested at low MOI as previously described,23 chimeric-1829 transduced
CS1 cells significantly more efficiently (data not shown). We tested the transduction efficiency
of chimeric-1829 and parental serotypes on a large panel of human and murine melanoma cells
of both recently or long-standing derivation. As shown in Table 1 and Figure 3b, AAV2 and
chimeric-1829 could efficiently transduce human melanoma cell lines that have been in long-
term culture, but neither efficiently infected recent primary cultures of two human melanomas
(UNC Mel 1.2 and UNC Mel 3.1, both <14 days in culture). Interestingly, transduction
efficiency of AAV2 in all mouse melanoma cell lines was markedly lower than that displayed
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by chimeric-1829. Of the mouse and human cell lines tested, AAV1 transduced only two human
cell lines (A375 and WM-2664 at moderate and low efficiency, respectively), whereas AAV8
and AAV9 did not transduce any of these cell lines (Table 1 and Figure 3b). Heparin-inhibition
studies were then carried out as described.12 As shown in Figure 3c, preincubation of
chimeric-1829 capsids with soluble heparin (30 μg/ml; Sigma, St Louis, MO) blocked
transduction in both CS1 hamster melanoma and HEK293 cells suggesting that chimeric capsid
utilizes heparan sulfate as a primary receptor in vitro.
Biological characterization of chimeric-1829 vectors in vivo
Although we initially selected our chimeric library on CS1 cells do to lack of AAV2 coreceptor
and reduced susceptibility for vector transduction, we explored the ability of chimeric-1829 to
transduce these tumor cells in vivo using severe combined immunodeficiency mice and CS1
derived tumors. We observed a three-and fivefold increase in transduction in vivo when
comparing chimeric-1829 with serotypes 1 and 2 (Supplementary Materials and Methods).
Types 8 and 9 did not transduce the CS1 target cells in this model (data not shown). Although
we observed the ability to transduce target cells after direct injection, we did not detect
transduction of target cells after tail vein injection, but instead observed a unique transduction
pattern compared to controls (data not shown) and therefore decided to further explore this
observation in normal mice to ensure these results were not influenced by the mouse
background (e.g., severe combined immunodeficiency). The general transduction profile of
chimeric-1829 in vivo in C57BL/6 was carried out using CBA-Luc cassette and injected into
mice through different routes. As indicated by the representative bioluminescent images
(Figure 4a and b), transgene expression levels in skeletal muscle and liver, obtained by
intramuscular or intravenous injection of chimeric-1829 were much lower in comparison with
AAV1 and AAV2. Corresponding injections with AAV8 and AAV9 vectors result in widely
disseminated and high transgene expression levels in contrast to that obtained with chimeric
capsid (data not shown).
We extended this analysis to rodent brain as melanocytes and neuronal precursors share a
common lineage. In rat brain, extensive studies have shown that AAV serotypes 1, 2, 8, and 9
exhibited a predominant neuronal tropism,32-34 but this common tropism did not prove to be
the case for chimeric-1829. As seen in Figure 4c, 1 month after infusion of AAV1829, the
general pattern of transduction proved quite distinct from that of AAV2 (Figure 4c, panel A
versus panel B, respectively). The vast majority of chimeric-1829-transduced cells did not
colocalize with the neuronal marker NeuN (Figure 4c, panels C–E) or the astrocyte marker
glial fibrillary acidic protein (Figure 4c, panels F–H) as previously shown for serotypes 1, 2,
8, and 9.32-34 However, a number of GFP positive cells did colocalize with nestin, indicative
of neuronal fated progenitor cells, reactive astrocytes, or type I astrocytes.35,36 In marked
contrast, the vast majority of AAV2-transduced cells colocalized with NeuN, a marker for
neurons (Figure 4c, L–M). These studies were further corroborated by in vivo studies in monkey
brains following injection into the caudate nucleus or the substantia nigra using AAV2 and
chimeric-1829. As shown in Figure 4d, chimeric-1829 demonstrates a markedly reduced
tropism for primate neurons in comparison with control. Figure 4e and f describe the reduced
efficiency of transduction and spread of chimeric-1829 compared to AAV2 in caudate and
substantia nigra further demonstrating the unique tropism of this vector.
Neutralizing antibody titers and crossreactivity
Based on modeling residue, the amino acid stretch from 264 to 272 derived from AAV1 forms
a minor part of the A20 epitope.30,31 We tested chimeric-1829 in an enzyme-linked
immunosorbent assay to see whether these structural amino acids contributed or interfered with
A20 recognition. Figure 5a shows complete loss of A20 binding to chimeric-1829 when
compared to AAV2 control suggesting a change in this structural epitope. In order to understand
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the immunological profile of chimeric-1829 with parental serotypes, neutralizing antibody
(NAb) titers were analyzed by assessing the ability of serum antibody to inhibit vector
transduction. NAb titers shown are reciprocals of the highest serum dilution leading to a 50%
decrease in transduction levels. Sera from mice that received the booster injection exhibited
NAb titers ranging from 1,000 to 10,000 (Figure 5b and c). As shown in Figure 5b, the antisera
from AAV1-, AAV8-, and AAV9-immunized mice do not crossreact with chimeric-1829.
Antisera from AAV2-immunized mice display some crossreactivity, albeit at a 25-fold lower
NAb titer. In corollary, antisera against chimeric-1829 do not crossreact with AAV1, AAV8,
or AAV9, while displaying crossreactivity with AAV2 capsids at a 25-fold lower NAb titer
(Figure 5c). It is noteworthy to mention that AAV1 and AAV9 residues that differ from AAV2
are located in a minor A20 epitope and an antigenic region, respectively, previously identified
on the AAV2 capsid.30 It is likely that such location of residues derived from other serotypes
might play a role in the differential antigenic reactivity exhibited by chimeric-1829 in
comparison with parental serotypes.
Mapping domains contributing to the melanoma-specific tropism of chimeric-1829
In chimeric-1829, the AAV8 and AAV9 regions, which include amino acid residues 410–450
and 705–736, are close to the twofold interface and lie in regions potentially critical for AAV
transduction.30 Moreover, both regions differ among serotypes by less than 10 amino acids or
so, enabling rational mutagenesis of single amino acid residues within these critical regions.
In the AAV8 region, only three amino acids are different from other serotypes. Among these,
the 413T and 418D are similar to 413S and 418E seen in the VP3 subunit of AAV2. The Q411T
mutant (Figure 6a, 9) demonstrated no significant change in transduction efficiency in
comparison with chimeric-1829 (data not shown). To elucidate the role of the AAV9 region
in melanoma tropism of chimeric-1829, we then generated a series of chimeric cap genes by
swapping individual capsid domains from one serotype to the other as well as some point
mutations through site-directed mutagenesis. As shown in Figure 6a, the AAV2 and AAV9 C-
terminal residues (705–735) were swapped onto chimeric-1829 and AAV2, respectively
(Figure 6a, 2 and 3). Four additional mutants, [chimeric-1829Y706N, A714T, N716D, and
E718N (Figure 6a, 4–7)] were generated to identify the role of single residues in the C-terminal
region. Two other residues (N709V and E712D) at positions in the AAV9 region were omitted
because of high degree of similarity with the corresponding AAV2 C-terminal region. In
addition, we swapped the AAV1 C terminus (705–735) onto chimeric-1829. However, this
construct proved to be defective in packaging vector genomes and was not explored any further.
As shown in Figure 6b, based on GFP transgene expression in CS1 cells, a spectrum of
transduction efficiencies with the following hierarchy was seen: chimeric-1829 was most
efficient in transducing CS1 cells, followed by E718N (no. 7), Y706N (no. 4), N716D (no. 6),
A714T (no. 5), AAV29 (no. 3), and AAV182 (no. 2), in that order. This hierarchy is more or
less consistent with the quantitative luciferase transgene expression obtained in CS1 cells with
aforementioned mutants (Figure 6c). When the C-terminal residues (705–735) of
chimeric-1829 were replaced with those of AAV2, transduction efficiency of the resulting
chimeric vector decreased by nearly one order of magnitude, implicating this region as playing
a critical role in melanoma cell tropism of chimeric-1829. However, in corollary, when the C-
terminal domain from AAV9 was swapped onto AAV2, a modest decrease in transduction
efficiency was seen.
DISCUSSION
In this study, we carried out DNA shuffling of AAV capsid genomes corresponding to AAV
serotypes 1–9 to generate a chimeric AAV library. Until recently, attempts to elucidate
structure–function attributes of the AAV capsid have primarily focused on site-directed and
Li et al. Page 5













insertional mutagenesis, including epitope-tag or ligand-insertion mutants and epitope
substitution mutants.14 However, such strategies are often biased toward regions previously
identified as potential sites for manipulation. Starting with no prior knowledge of the best
serotype to choose or the number of mutations needed to generate new phenotypes, random
mutagenesis of any single parent would require libraries that are orders of magnitude larger.
Thus, we rationalized that the application of molecular breeding to the AAV family in
conjunction with rational mutagenesis should enable high-throughput characterization of
critical domains on AAV serotype capsids as well as the accelerated evolution of novel tissue-
specific AAV vectors.
As proof of principle, a chimeric virus composed of capsid sequences from AAV1, 8, 2, and
9 was obtained through selection in a hamster melanoma cell line (Figure 1). Selection of
chimeric library on CS1 cell has preferentially selected a chimeric particle with enhanced
tropism for CS1 cell line compared to parental donors (Figure 3a). However, this tropism is
not unique to CS1 integrin minus cells but extends to all rodent melanoma cell lines tested
regardless of absence or presence of integrin (see Figure 3, Table 1). Although chimeric-1829
transduced these cells readily, none of the parental donor capsids was able to infect the rodent
melanoma cells demonstrating that in the case of this chimeric capsid, the whole is the best of
the parts. We then expanded our study to characterize the transduction profile of chimeric-1829
in a range of human melanoma cell lines and cultures. Interestingly, chimeric-1829 displayed
transduction efficiencies comparable to parental AAV2 vectors in all human cells, while
parental serotypes 8 and 9 were negative and type 1 restrictive to transducing one of nine cell
lines (Figure 3b, Table 1). It is tempting to speculate that such selective tropism for hamster/
mouse melanoma cells displayed by chimeric-1829 could arise from the ability of the capsid
to exploit a species-specific cellular factor (such as a cell surface coreceptor) for rodent
melanoma cell entry. Although this critical finding highlights a potential caveat associated with
application of this technique in developing AAV vectors for human gene therapy, it is important
to note that the strategy allows elucidation of the determinants of species-specific differences
in AAV serotypes. Obvious solutions to this problem are the use of human cell lines and
“humanized” mouse models for directed evolution.
Following the isolation of such cell type–specific mutant(s), we utilized a battery of structural
and molecular cloning tools to further investigate specific domains and residues that might
potentially constitute determinants for melanoma cell–specific tropism in chimeric-1829.
Structural analysis of a 3D model generated for the chimeric-1829 vector suggests that the
heparin-binding regions are derived from AAV2, while antigenic regions were derived from
more than one serotype capsid (Figure 2b and c). These results were further corroborated
through heparin-inhibition studies (Figure 3c) and characterization of the immunological
profile of chimeric-1829 (Figure 5a–c). In particular, the unique immunological profile of
AAV1829 in comparison with its parental serotypes is an important finding reported in this
study (Figure 5). We observed low-to-modest crossreactivity of NAbs against chimeric-1829
with AAV2 capsids (25-fold) and no crossreactivity to parental capsids 1, 8, or 9. The primary
outcome of this analysis suggests that antigenic regions on the AAV capsid can be manipulated
by grafting domains derived from other serotype capsids. This approach could aid in the
generation of NAb escape mutants relevant for vector readministration in a clinical setting.
The generation of chimeric mutants through rational mutagenesis was a critical component in
establishing the molecular determinants for melanoma tropism displayed by chimeric-1829. A
cumulative assessment of mutants generated through domain swapping and site-directed
mutagenesis suggests that the C-terminal residues derived from AAV9 likely play a necessary,
but not sufficient, role in conferring melanoma cell tropism to the chimeric-1829 capsid. In
particular, we demonstrated that residues derived from AAV9, which form the wall of the
twofold dimple, could play an important role in transducing CS1 hamster melanoma cells. This
suggests that this region likely interacts with a yet unidentified cellular factor, or potentially
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involved in capsid structural/conformational transitions that are important for efficient rodent
melanoma cell entry and transduction. It is worth noting that we recently generated a chimeric
AAV capsid currently being used in a phase I clinical trial for Duchene muscular dystrophy.
In this vector, three of the five amino acids that were altered to enhance skeletal muscle
transduction were also located in the 705–735 amino acid region, independently confirming
the importance of this domain in AAV infectivity (Bowles and R.J.S., unpublished results).
In addition to displaying selective tropism for melanoma cells in vitro, chimeric-1829 displays
tropism for CS1 cells in severe combined immunodeficiency model (Supplementary Materials
and Methods) and altered tropism for murine liver and skeletal muscle in vivo (Figure 4a and
b). Although modest, such “detargeting” of capsids vectors, in conjunction with tropism for
specific cell types, could afford greater control over the biodistribution of viral vectors, thereby
avoiding potential side effects due to transduction of nontarget tissues in vivo. It is further
corroborated through our vector-infusion studies in the rat brain (Figure 4). Previous studies
have shown that the parental serotypes of chimeric-1829 exhibit a preferential tropism for
neurons.32-34 In contrast, chimeric-1829 appears to exhibit reduced tropism for neurons in
both rat and monkey brains and potentially, preferential tropism for glial fibrillary acidic
protein/nestin positive non-neuronal cells of rodent origin. Besides the fact that most melanoma
metastasizes to the brain (54%),24 neuronal precursors (nestin positive cells) in the central
nervous system and melanocytes are derived from a common linage (neural crest). As a number
of brain tumors demonstrate surface markers similar to progenitor cells (nestin positive), which
suggests reversion back to an earlier precursor cell type, we realized that the ability of
chimeric-1829 to transduce a selected cell population may suggest a common link between
these central nervous system cell types and the fact that they may share a similar lineage
pathway with melanocytes. Thus, DNA shuffling/directed evolution proves capable of
dramatically shifting capsid in vivo tropism.
In summary, we have described the utilization of DNA shuffling of a family of AAV capsid
genes and directed evolution to generate a chimeric capsid library and a cell type–specific
chimeric particle isolate (i.e., 1829), respectively. Further exploitation of the capsid library for
isolation of novel chimeric mutants in vitro and in vivo is currently in progress (airway, heart,
and brain; W.L., unpublished results) and likely to yield new capsid vectors with altered
tropisms and antigenic profiles. More important, we anticipate that the mutants generated
through shuffling of AAV serotype–specific capsid motifs or capsid sequences from similar
(B19) or divergent (SV40, Ad, etc.) viruses will lay the foundation for designing the next
generation of novel vectors for human gene therapy applications namely “biological
nanoparticles” that process unique tissue targeting, immune profiles, and biodistribution.
MATERIALS AND METHODS
Cells and viruses
HEK293 and CS1 cells (a gift from David Cheresh, University of California at San Diego)
were maintained at 37 °C in a 5% CO2 atmosphere in Dulbecco’s modified Eagle’s medium
(Sigma) supplemented with 10% fetal bovine serum and penicillin–streptomycin (100 U/ml).
Ad dl309 has been described previously.37 For human melanoma cell lines UNC Mel 1.2 and
3.1, the primary melanomas were disaggregated in 0.25% trypsin–EDTA and then grown on
uncoated plastic in Dulbecco’s modified Eagle’s medium with the addition of 10% fetal bovine
serum, penicillin–streptomycin, and 50 μmol/l β-mercaptoethanol (Gibco, Grand Island, NY).
Human melanoma cell lines were cultured at 37 °C in 5% CO2 atmosphere in Dulbeccos
modified Eagle’s medium (Gibco), with the addition of 10% fetal bovine serum, penicillin–
streptomycin, and 50 μmol/l β-mercaptoethanol. For human melanoma cell lines, A375,
A2058, Mel505, UACC-257, PMWK, WM-2664, and SKMEL-24, the sources and handling
of these lines were shown as described.38 For culturing of murine tumor cell lines, KPTR1,
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KPTR4, KPTR5, KPTR6, KR287T1, KR287T2, KR389, primary murine tumors were handled
as described.39,40 All human studies were performed in accordance with the University of
North Carolina (UNC) Institutional Review Board, and all murine studies in accord with the
UNC Institutional Animal Care and Use Committee.
Construction of the chimeric plasmid library
The DNA shuffling procedure using the JBS DNA shuffling kit has been described previously.
41 In brief, the sequence of helper plasmids pXR and two sets of primers were designed in a
nested configuration. The outer primers, P1 and P2 were used to amplify DNA for the
fragmentation reaction. The 4.4-kilobase fragment encompassing the entire Cap, part of the
Rep gene and part of the plasmid backbone sequence was amplified from each of eight parental
AAV helper plasmids (pXR1-6,8,9). The PCR products were then mixed together in equimolar
amounts and subjected to random fragmentation by DNaseI. Fragments ranging from 400 to
1,200 base pair in size were resolved in an agarose gel and reassembled through cycles of
denaturation, annealing, and extension in the absence of primers. Cycling was performed as
follows: 96 °C, 90 seconds; 35 cycles of (94 °C, 30 seconds; 65 °C, 90 seconds; 62 °C, 90
seconds; 59 °C, 90 seconds; 56 °C, 90 seconds; 53 °C, 90 seconds; 50 °C, 90 seconds; 47 °C,
90 seconds; 44 °C, 90 seconds; 41 °C, 90 seconds; 72 °C, 4 minutes); 72 °C, 7 minutes; and
finally 4 °C. The assembled fragments were then amplified using inner primers P3 and P4,
digested with SfiI and XbaI, and ligated into the pSSV9 backbone digested with the same
enzymes. Ligation mixtures were column purified and transformed into competent DH10B
cells.18 Plasmid library diversity was determined by counting the number of clones obtained
from a representative aliquot of transformed bacteria on agar plates containing 100 μg/ml
ampicillin. The entire transformation mixture was plated on agar plates and plasmid DNA
isolated from pooled clones without further growth in liquid culture. To assess the diversity of
the generated library, 20 sample clones from the library were subjected to sequence analysis.
Primer sequences are listed in the Table 2.
Generation of AAV library transfer shuttles and the chimeric AAV capsid library
As described previously,8 the chimeric AAV library was generated using the plasmid library
through a two-step process. First, AAV genomes from the shuffled plasmid library were
partially packaged into AAV2 capsids. This was achieved by transfecting HEK293 cells grown
in 10 15-cm plates with a 1:1:2 ratio of the pXR2 plasmid (containing AAV2 Rep and Cap
genes without inverted terminal repeats), the plasmid library, and the pXX6-80 helper plasmid
(60, 60, and 120 μg, respectively). The resulting AAV library transfer shuttles were harvested,
and purified by CsCl gradient ultracentrifugation (~400,000 g/5 h) using a Beckman NVT65
rotor in a Sorvall Ultra 80 centrifuge. The chimeric AAV capsid library was then generated by
infecting HEK293 cells with AAV library transfer shuttles (MOI = 1) followed by super-
infection with Ad dl309 (4 plaque forming units/cell). Cells were then harvested after 36 hours
and the chimeric AAV capsid library encapsidating their respective chimeric genomes were
purified as described earlier.
Isolation of cell type–specific AAV vectors
Target CS1 cells were coinfected with the AAV capsid library (MOI = 1,000) and adenovirus
dl309 (MOI = 20) and incubated at 37 °C for 48 hours. The cells were then harvested after 48
hours, rinsed with 5 ml phosphate-buffered saline, resuspended in 1 ml phosphate-buffered
saline, and lysed through freeze–thaw cycles (3×). Cellular debris was then removed by
centrifugation and a fraction of the supernatant used to infect the next batch of target cells for
the second cycle of selection. After each round of selection, viral genomic DNA was purified
from 50 μl aliquots of crude cell lysates using the DNeasy kit (Qiagen) for determination of
viral genome titer by dot blot hybridization. DNA extracted from cell lysate after the fifth cycle
Li et al. Page 8













served as a template for PCR using primers P3 and P4 described previously. The amplified
PCR fragment was then subjected to sequence analysis and cloned into the pXR2 backbone.
Physical characterization of chimeric-1829
Sequence analysis and alignment of the variant sequence with parental serotype sequences was
carried out using VECTOR NTI10. The 3D model of VP3 trimers and pentamers of the capsids
of chimeric-1829 isolates were generated using SWISS MODEL with coordinates from the
AAV2 crystal structure (PDB ID: 1lp3) serving as template. Subsequent surface rendering and
mapping of regions derived from different AAV serotypes were performed using Pymol
(http://www.pymol.org). Recombinant vectors encapsidating GFP or firefly luciferase
transgenes driven by the cytomegalovirus or chicken β-actin (CBA) promoter, respectively
were produced as described previously.42 Viral titers were determined using DNA dot blot
hybridization. Heparin-binding studies with the chimeric-1829 isolate were carried out as
described earlier.43-45
Biological characterization of chimeric-1829
Heparin-inhibition assay—The heparin-inhibition assay was performed as described
previously.43 In brief, 24 hours before infection, chimeric-1829/GFP vectors (MOI = 5) were
incubated in the presence of heparin at 30 μg/ml for 1 hour at 37 °C. Cells were then washed
2 hours later. GFP expression was monitored 48 hours after infection using a Nikon TE-300
inverted fluorescent microscope.
In vitro transduction assays—The transduction efficiency of parental AAV serotypes
used in generating the AAV library and novel isolate, chimeric-1829, were determined in target
CS1 melanoma cells. In brief, CS1 cells were transduced with chimeric-1829 carrying the GFP
transgene cassette [1,000 vector genomes (vg)/cell] and transgene expression was monitored
48 hours after infection using a Nikon TE-300 inverted fluorescent microscope.
In vivo studies—The chimeric-1829 vector packaging the CBA-Luc transgene was
administered to C57BL/6 mice through the intramuscular (hindlimb, 1010 vg) or intravenous
(tail vein, 1011 vg) routes. One month later after administration, luciferase transgene expression
levels were determined using the Xenogen IVIS system. For in vivo brain study materials, see
Supplementary Materials and Methods.
NAb titers and crossreactivity
Balb/c mice were injected with the chimeric-1829 vector or corresponding parental vectors
chimeric-1829 (5 × 1010 vg) by subcutaneous injection and a booster dose 2 weeks later. After
another 2 weeks, sera from mice were analyzed for NAb titer and crossreactivity by assessing
the ability of serum antibody to inhibit AAV vector transduction. In brief, various dilutions of
antibodies were preincubated with reporter virus for 1 hour at 37 °C and added to Hela/U87MG
cell cultures. GFP expression cells were then countered using fluorescent microscope. NAB
titers were calculated as the highest serum dilution inhibiting transduction by 50% of that
determined for control (vector plus serum from naive animals).
Enzyme-linked immunosorbent assay with monoclonal antibody A20
Serial dilutions of AAV variants (2 × 1011vg/100 μl) were added to each well of a 96-well
micro-titre plate. Plates were incubated at 4 °C overnight in 100 μl blocking buffer (0.1 mol/l
phosphate-buffered saline with 1% bovine serum albumin) followed by incubation at 37 °C
for 1 hour. Plates were then washed three times with phosphate-buffered saline–Tween, 100
μl of A20 antibody was added (15× dilution) and incubated at 37 °C for 1 hour. After three
washes and incubation with 100 μl of anti-mouse horseradish peroxidase–conjugated antibody
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(5,000 times dilution; Pierce), plates were washed three times, 100 μl of 3.3′, 5.5′-
tetramethylbenzidine substrate solution was added (PBL) to each well followed by incubation
in the dark for 15 minutes. Finally, 100 μl stop solution (PBL) was added to each well and
pictures obtained with a scanner.
Site-directed mutagenesis
Chimeric-1829 mutants were generated by performing QuikChange site-directed mutagenesis
(Stratagene) on plasmids pXR1829 according to manufacturer instructions. In addition,
domain-swapped chimeras were obtained using PCR and restriction digestion techniques to
exchange fragments between chimeric-1829 and its parental serotypes. Primer sequences are
listed in Table 2.
Structural analysis of the chimeric-1829 vector
A structural model of the chimeric-1829 virus was generated using the SWISS-MODEL online
3D model building server with the crystal structure of AAV2 supplied as template (23, PDB
ID: 1lp3).46 The contributions of the four parental serotypes AAV1, 8, 2, and 9 to the chimeric
vector were analyzed in the graphics program O and figures showing the serotype contributions
were generated using the program Pymol.47,48
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(a) Strategy for generating a combinatorial adeno-associated virus (AAV) library that will be
subjected to directed evolution to isolate cell type/receptor-specific AAV mutants. AAV Cap
genes were randomly fragmented and reassembled using cycles of denaturation, annealing,
and extension using PCR. Following this reassembly reaction, PCR amplification with specific
primers was used to generate full-length Cap chimeras for cloning into wild-type AAV2
backbone to generate shuffled plasmid library. AAV particle library was generated by plasmid
transfection protocol. Specific cell line (hamster melanoma CS1 cells) previously shown to be
restricted to transduction of AAVs will be tested with the chimeric AAV library for a premissive
clone. Subsequent steps will involve development of novel AAV variants as targeted vectors
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for in vivo gene delivery applications. (b) Dot blot demonstrating the directed evolution of cell
type–specific AAV variant from CS1 cells after five infectious cycles (n = 5). Data are shown
in duplicate. ITR, inverted terminal repeat.
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Figure 2. Physical characterization of chimeric-1829
(a) Primary structure of novel adeno-associated virus (AAV) variant selected from CS1cell.
(b) Three-dimensional model showing VP3 subunits of AAV1829 in relation to the fivefold
(white pentagon); threefold (white triangle) and twofold (white oval) axes of symmetry.
AAV1-derived residues are colored salmon, AAV2 in blue, AAV8 in dark pink, and AAV9 in
yellow. (c) Black box region in 2. Panel b shown at higher magnification. Key residues in the
C-terminal AAV9 region that differ from AAV2 are colored gray (706); cyan (709); orange
(712); green (714); white (716); and black (718) using Vp1 numbering. (d) Heparin binding
profiles of AAV1829 and AAV2. L, load; FT, flow through; W, wash; e, elution.
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Figure 3. Biological characterization of chimeric-1829 compared with some parental serotypes
(a) Fluorescence micrographs of green fluorescent protein (GFP) transgene expression in CS1
cells transduced with AAV serotypes 1–9 (except 7) and the novel variant chimeric-1829 at a
multiplicity of infection (MOI) of 1,000 for 48 hours. (b) Representative fluorescence
micrographs of GFP transgene expression in different human and mouse melanoma cell lines
infected with chimeric-1829 and parental serotypes at an MOI of 1,000 for 48 hours. (c)
Heparin-inhibition assay. Top panels show CS1 cells, and bottom panels show 293 cells. Left
and right columns are transduction profiles in the absence and presence of heparin, respectively.
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Figure 4. In vivo transduction ability compared with some parental serotypes
(a) Luciferase transgene expression in the hindlimbs of Balb/C mouse injected with 1010 vector
genomes of the novel adeno-associated virus (AAV) variant and parental AAV1, 2.
Bioluminescent images were obtained at the end of 1 month using a Xenogen IVIS system.
(b) Luciferase transgene expression in the liver through tail vein injecton of 1011 vector
genomes of the novel AAV variant and parental AAV1, 2. Bioluminescent images were
obtained at the end of 1 month using a Xenogen IVIS system. (c) Patterns of transduction in
the rat striatum 1 month after a 1 μl infusion of either AAV1829 or AAV2. (d) Comparison of
the transduction efficiency of AAV2 and chimeric-1829 after injections into the (a and c)
caudate nucleus and (b and d) substantia nigra of monkeys after immunostaining for green
fluorescent protein (GFP). Scale bar = 50 μm. (e,f) Stereological counts of GFP-labeled cells
and area of spread after each vector show that AAV2 shows greater transduction efficiency
over a larger volume than chimeric-1829 in these areas.
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Figure 5. Neutralizing antibody (Nab) titer and crossreactivity
(a) Enzyme-linked immunosorbent semi-quantitative assessment of the affinity of
chimeric-1829 and adeno-associated virus-2 (AAV2) to A20 (AAV2 molyclonal antibody),
for details see Materials and Methods. (b) NAb titer of parental serotypes sera and their
crossreactivity against AAV1829. (c) NAb titer of chimeric-1829 sera and it’s crossreactivity
against parental serotypes.
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Figure 6. The transduction efficiency of chimeric-1829 and its mutants
(a) Diagram of the chimeric capsid constructs and site point mutants. (b) Fluorescence
micrographs of green fluorescent protein transgene expression in CS1 cells transduced with
AAV1829 and its mutants at a multiplicity of infection (MOI) of 1,000 for 48 hours. (c)
Luciferase transgene expression in CS1 cells transduced with AAV1829 and its mutants at an
MOI of 1,000 for 48 hours. 1, Chimeric-1829; 2, AAV182; 3, AAV2–9; 4, chimeric-1829
Y706N; 5, Chimeric-1829 A714T; 6, Chimeric-1829 N716D; 7, Chimeric-1829 E718N; 8,
AAV2; 9, AAV129. AAV, adeno-associated virus; RLU, relative luciferase unit.
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